logo
Researchers Discovered a Rare 13th-Century Manuscript. It Was Hiding in Plain Sight All Along.

Researchers Discovered a Rare 13th-Century Manuscript. It Was Hiding in Plain Sight All Along.

Yahoo17-04-2025

A fragment of a 13th century piece of French prose was discovered, having been used as the binding for pages of a 16th-century property record in the University of Cambridge library.
The fragment was a portion of a manuscript, Suite Vulgate du Merlin—fewer than 40 examples of which have survived.
The team was able to 'virtually unfold' the fragment without damaging the artifact itself.
This story is a collaboration with Biography.com
As the great astronomer Carl Sagan once said: 'If I finish a book a week, I will read only a few thousand books in my lifetime, about a tenth of a percent of the contents of the greatest libraries of our time.' And that is not even considering the books that may, apparently, be hiding inside the binding of other books.
That's something Cambridge University Library had to contend with in 2019, when they found that a property record from Huntingfield Manor in Suffolk was bound together by an even older manuscript, previously undiscovered. Now the book which became binding has been identified, and it's safe to say it's a bit more of a page-turner than the pages it once bound together.
In a recently published article, the University of Cambridge announced that the uncovered manuscript has been deciphered, digitized, and determined to be a fragment of the prose work Suite Vulgate du Merlin. Described by Cambridge as a 'French-language sequel to the legend of King Arthur,' this work was part of a larger story cycle written in approximately 1230-1240 known as the Lancelot-Grail cycle.
While most may not be reading Suite Vulgate du Merlin today, it's more a part of our understanding of Arthurian legend than we might realize. As noted in Romance Rewritten: The Evolution of Middle English Romance, this particular work was likely one of the major sources utilized by Sir Thomas Mallory in writing his 1485 Le Morte d'Arthur—the most famous and influential English-language telling of the King Arthur story.
'There are less than 40 surviving manuscripts of the Suite Vulgate du Merlin,' Cambridge notes, 'with each one unique since they were individually handwritten by medieval scribes.' This specific fragment, written in Old French, contained two stories from the latter portion of the Suite Vulgate. The first depicts the Battle of Cambénic, where the famed Arthurian figure Sir Gawain (written here as Gauvain)—wielding Excalibur atop his horse, Gringalet—does battle with the Saxon Kings Dodalis, Moydas, Oriancés, and Brandalus. This particular manuscript, it was noted, spelled Dodalis' name as Doralis.
The second episode described Merlin arriving at King Arthur's court during the Feast of the Assumption of the Virgin Mary, disguised through his magic as a harpist. In their article, Cambridge published an excerpt of their translation:
'While they were rejoicing in the feast, and Kay the seneschal brought the first dish to King Arthur and Queen Guinevere, there arrived the most handsome man ever seen in Christian lands. He was wearing a silk tunic girded by a silk harness woven with gold and precious stones which glittered with such brightness that it illuminated the whole room.'
But translating the fragment was more than just a challenge of linguistics. 'Traditional methods of conservation might have involved physically removing the binding to unfold the fragment,' they note, 'but this risked causing irreparable damage.'
'It's not just about the text itself, but also about the material artifact,'
Irène Fabry-Tehranchi, a French specialist in collections and academic liaison at Cambridge University Library, said. 'The way it was reused tells us about archival practices in 16th-century England. It's a piece of history in its own right.'
Having ultimately decided to leave it be, the university then had to find a way to 'virtually unfold and digitise' the fragment without removing it. This process required a multidisciplinary team from across numerous departments, but through an arduous sequence of efforts—including multispectral imaging, computed tomography (CT) scanning, and 3D imaging—experts were able to manipulate this digital replica of the fragment in order to 'simulate what the document might look like if it were physically opened.'
Both the discovery of the fragment and the manner in which it was deciphered could serve as inspiration for medieval research in the future. It reminds researchers to look for these lost works in places they might not expect, and demonstrates how to save the stories they contain from the ravages of time—without ruining the pages that hold them.
It may not be a spell from Merlin, but it's a type of magic all its own.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Solar-Powered Slug Steals Chloroplasts and Stores Them for Emergency Food
Solar-Powered Slug Steals Chloroplasts and Stores Them for Emergency Food

Yahoo

timea day ago

  • Yahoo

Solar-Powered Slug Steals Chloroplasts and Stores Them for Emergency Food

'Solar-powered' sea slugs have specialized depots in their cells that store photosynthetic equipment looted from algae, a study reports. These depots provide just the right chemical environment to keep the stolen apparatus, called chloroplasts, alive and working to turn sunlight into nutrients. 'It was the wildest thing that we had seen,' says study co-author Nicholas Bellono, a biologist at Harvard University in Cambridge, Massachusetts. The authors also found that, in lean times, the slugs can raid these compartments to consume chloroplasts. The compartment 'is basically like a moving refrigerator of chloroplasts where, after a period of starvation, the slugs can switch from storage to consumption to survive', Bellono says. [Sign up for Today in Science, a free daily newsletter] The findings were published in Cell. Scientists discovered decades ago that certain species of sea slug store chloroplasts from the algae they eat, a diet that can turn the slugs bright green. But no one understood how the slugs keep these foreign organelles alive without the support of the rest of the algal cell. Bellono and his team added chemical tags to proteins newly made by the slugs' own cells. They found that most of the proteins in a slug's chloroplasts were made by the slug — not by the original algae. That meant the slug was helping to maintain the chloroplasts. When the scientists looked at the chloroplasts under a microscope, they found that the organelles were housed in special compartments in the slugs' guts. Each compartment was surrounded by a membrane that tested positive for markers typically found in cellular structures called phagosomes, which fuse with other structures called lysomes to digest unneeded organelles. The researchers named this structure the kleptosome, after a Greek word that means to steal. The team also found that these organelles contained ion channels — receptors that convert chemical messages into electrical signals. Among them is one called P2X4, which opens in response to the presence of ATP, an energy-carrying molecule produced during photosynthesis. When Bellono and his team blocked this channel in slugs' kleptosomes, oxygen production from photosynthesis dropped, showing that the kleptosome is actively involved in keeping the chloroplasts functioning. Having discovered the existence of the kleptosome, the researchers wondered whether it helps the slugs to resist starvation. They compared the solar-powered slug Elysia crispata with Aplysia californica, a non-photosynthetic slug that lacks kleptosomes. Aplysia died after three to four weeks without food, whereas Elysia could survive for up to four months. Yet, after four weeks, the Elysia slugs lost their green colour, turned orange — just as leaves do in autumn — and stopped photosynthesizing. Microscopy revealed that the Elysia's kleptosomes had begun fusing with lysosomes and that the colour change was caused by the degradation of the chloroplast. The study is 'remarkable,' says cell biologist Elena Oancea at Brown University in Providence, Rhode Island. Studying the molecular and cellular processes of creatures as small as sea slugs is extremely challenging, she says. 'It takes a lot of courage to do that.' The discovery of the kleptosome could help to answer broader questions about organelle evolution and other cellular processes that we don't understand yet, Oancea says. All life is built on cells, she adds: 'It's the basic principle of nature.' This article is reproduced with permission and was first published on June 25, 2025.

Vor, with new CEO, changes course to target autoimmune disease
Vor, with new CEO, changes course to target autoimmune disease

Yahoo

timea day ago

  • Yahoo

Vor, with new CEO, changes course to target autoimmune disease

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vor Biopharma is licensing rights to an immune disease drug from Chinese biotechnology company RemeGen, it said Wednesday, a little over one month after announcing plans to review strategic alternatives. As part of its shift in focus, Vor also announced it appointed former MorphoSys leader Jean-Paul Kress as CEO. Vor's previous chief executive Robert Ang will stay on as an adviser through October. Vor also raised $175 million in a PIPE, or private investment in public equity, that involved half a dozen investors including RA Capital Management, Forbion and Venrock Healthcare Capital Partners. PureTech Health and the oncologist and author Siddhartha Mukherjee founded Vor nearly a decade ago. Progress developing a treatment for leukemia led the company in 2021 to price a $177 million initial public offering. But a rocky few years forced Vor to change direction. The Cambridge, Massachusetts-based biotech had been advancing cell therapies called trem-cel and VCAR33, but in May revealed plans to wind down clinical operations and lay off 95% of its employees. Now, Vor is reestablishing itself as an autoimmune disease company. The deal with RemeGen gives its rights to develop and commercialize in most parts of the world a drug for generalized myasthenia gravis, systemic lupus erythematosus and rheumatoid arthritis that's already approved in China. Vor is paying RemeGene $45 million upfront along with $80 million in warrants to purchase common stock in exchange for the drug, called telitacicept. Telitacicept is in Phase 3 testing for generalized myasthenia gravis in the U.S., Europe and South America, according to the companies. Data from that trial is expected in 2027. 'I am absolutely thrilled to be leading Vor Bio as we transform the company to become a major player in autoimmune disease treatment,' Kress said in a statement. Telitacicept's targets are cytokines known as BAFF and APRIL, which have also been the focus of other dealmaking. Recently, China-based biotechs like RemeGen are providing more and more of the drug candidates licensed by U.S. and European drugmakers. 'Global biopharma companies can increasingly look to China as a cost-effective source of innovation, particularly for validated targets and rapid generation of proof-of-concept data,' Leerink Partners analyst David Risinger wrote in a Thursday note to clients. Vor's decision to start anew with a Phase 3-ready drug candidate contrasts with the route preferred by some activist investors and analysts, who have pushed struggling biotechs to wind down and return cash to shareholders rather than try to reinvent themselves. Some, like Third Harmonic Bio and iTeos Therapeutics, have taken this course, while others have resisted the pressure 'I couldn't be more thrilled with this exciting new direction for Vor, and new leadership with the background and skills appropriate for this asset,' Ang, Vor's former CEO, wrote in a LinkedIn post. Shares in Vor nearly doubled on the news to trade around $1 apiece by Thursday afternoon. Recommended Reading Biopharma sector still growing despite layoff wave, Stifel report finds

Denis Villeneuve to direct next James Bond movie
Denis Villeneuve to direct next James Bond movie

CNN

time3 days ago

  • CNN

Denis Villeneuve to direct next James Bond movie

Denis Villeneuve, whose films have won several Oscars, will direct the next movie in the James Bond franchise, Amazon MGM Studios has announced. Villeneuve, a French-Canadian filmmaker best known for his work on 'Blade Runner 2049,' 'Arrival' and the 'Dune' movies, will work with executive producer Tanya Lapointe and producers Amy Pascal and David Heyman. 'Some of my earliest movie-going memories are connected to 007. I grew up watching James Bond films with my father, ever since Dr. No with Sean Connery. I'm a die-hard Bond fan. To me, he's sacred territory,' said Villeneuve in a statement released by Amazon MGM Studios Wednesday. 'I intend to honor the tradition and open the path for many new missions to come. This is a massive responsibility, but also, incredibly exciting for me and a huge honor,' he added. Villeneuve's most recent film, 'Dune: Part Two,' was widely acclaimed when it was released last year and he now has an opportunity to bring those talents to a storied franchise. 'We are honored that Denis has agreed to direct James Bond's next chapter. He is a cinematic master, whose filmography speaks for itself,' said Mike Hopkins, head of Prime Video and Amazon MGM Studios, in the statement. 'James Bond is in the hands of one of today's greatest filmmakers and we cannot wait to get started on 007's next adventure,' he added. Amazon MGM Studios took over the Bond franchise in February. Under the deal, Michael G. Wilson and Barbara Broccoli – the duo who brought the 007 films to theaters for more than 60 years – remain co-owners, having formed a new joint venture with Amazon MGM that handed over the creative reins and control of all future production to the Jeff Bezos-founded company. Amazon bought MGM in 2022 for $8.25 billion, acquiring the Hollywood studio's catalog of 4,000 movies and 17,000-plus TV shows. As part of the deal, Amazon gained possession of the rights to distribute all 27 of the movies based on Ian Fleming's books. MGM's Bond films are the studio's most lucrative intellectual property, having brought in billions since first releasing 'Dr. No' in 1962. The latest installment of the spy franchise, 'No Time to Die,' raked in more than $770 million at the global box office, making it the fourth-highest grossing film of 2021. Villeneuve and Amazon MGM Studios will now have to choose a new actor for the titular role, as Daniel Craig announced that 'No Time to Die' would be his last Bond movie. CNN's Liam Reilly contributed to this report.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store